In patients with Alzheimer’s disease, the tau protein changes its structure, forming deposits in the brain. This process is thought to contribute to the death of nerve cells. The researchers have shown that metformin counteracts the structural changes in tau. Hence, the drug could potentially prevent the formation of abnormal protein deposits and the death of brain cells. The team also shed light on the molecular mechanism by which metformin acts. If additional experiments on Alzheimer’s mice proceed positively, clinical studies could begin shortly.